Daniel Barber, SVP-Chief Strategy/Dev Officer at Aquestive Therapeutics, Inc. (AQST), bought 1,000 shares at $8.00 ($8K) on 2018-12-10, disclosed to the SEC on 2018-12-10.
Open-market purchase of $8k AQST by SVP-Chief Strategy/Dev Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Clearly above the average filing.
| Filing → |
| AQST | SELL | 2026-07-17 | $100K | — | Filing → |
| AQST | SELL | 2026-06-16 | $104K | — | Filing → |
| AQST | SELL | 2026-05-18 | $35K | — | Filing → |